Advisory Board

Medunik Canada’s Advisory Board is composed of industry experts and thought leaders who assist and advise us on topics ranging from partnership opportunities and the compliance of our regulatory submissions, to new technologies and clinical trial protocols.

As regulatory requirements have become increasingly complex, so has the role of our advisory board. Medunik Canada is proud to call upon the expertise of the following industry professionals:

 

Jean F. Campbell

Former Vice-President, Membership Development at the National Organization for Rare Disorders (NORD)

Jean Campbell is nationally recognized as one of the leading rare disease patient advocate with an impressive record of success in fundraising and corporate relations. After serving nearly two decades with the National Organization for Rare Disorders (NORD) she retired as Vice-President of Membership Development after spending over ten years mentoring and consulting with many nonprofit organizations and their board of directors. Under Jean's leadership, there was significant expansion of several of NORD's membership programs along with the creation of NORD's restricted research, medical meeting, organization mentor and clinical broadcast programs. Jean also played a key role in the establishment of the NORD Corporate Council, which has grown to 50 pharmaceutical and biotechnology companies.

Read more

Abbey S. Meyers

Former President of the National Organization for Rare Disorders (NORD)

Abbey S. Meyers is the founder and Past President of the National Organization for Rare Disorders (NORD), a coalition of national voluntary health agencies and a clearinghouse for information about little known illnesses. She was also Honorary President of the European Organization for Rare Disorders (EURORDIS)

Read more

Marlene E. Haffner, M.D., M.P.H.

Former FDA's Director of Orphan Product Development

Marlene E. Haffner, MD, MPH is a career Public Health clinician and administrator. She received her MD degree from the George Washington University School of Medicine and a Master of Public Health degree from the Johns Hopkins Bloomberg School of Public Health. She obtained further training in internal medicine, hematology and dermatology at the Columbia University School of Medicine and the Albert Einstein School of Medicine, both in New York. She is board certified in internal medicine. It was at the Albert Einstein College of Medicine that Dr. Haffner first became interested in the underserved and in rare diseases, as she was responsible for patients in the sickle cell clinic and performing research on abnormal hemoglobin.

Read more